MPT0E028

Research use only, not for human use.

MPT0E028 (MPT 0E028) is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells.

MPT0E028 (MPT 0E028) is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA; inhibits class I HDAC1, HDAC2, and class Iib HDAC6 with IC50 of 53, 106, and 29.5 nM, respectively, weakly inhibits HDAC8 (IC50=2.5 uM), but not for HDAC4 (IC50>10 uM); inhibits the growth of HCT116 and MDA-MB-231 cells with IC50 of 0.09 and 0.19 uM; inhibits HCT116 tumor xenograft in vivo without significant adverse effects, shows stronger anti-cancer efficacy than SAHA.Solid Tumors Phase 1 Clinical

MPT0 E028

Cell Cycle/DNA Damage

HDAC

HDAC

Cancer

Solid Tumors

1338320-94-7

344.39

C17H16N2O4S

>98% (HPLC)

——

O=C(NO)/C=C/C1=CC2=C(N(S(=O)(C3=CC=CC=C3)=O)CC2)C=C1

(E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide

(-20℃)

With Ice Pack

≥ 2 years